148 related articles for article (PubMed ID: 17348833)
21. Discovery of a rhodanine class of compounds as inhibitors of Plasmodium falciparum enoyl-acyl carrier protein reductase.
Kumar G; Parasuraman P; Sharma SK; Banerjee T; Karmodiya K; Surolia N; Surolia A
J Med Chem; 2007 May; 50(11):2665-75. PubMed ID: 17477517
[TBL] [Abstract][Full Text] [Related]
22. Modification of the NADH of the isoniazid target (InhA) from Mycobacterium tuberculosis.
Rozwarski DA; Grant GA; Barton DH; Jacobs WR; Sacchettini JC
Science; 1998 Jan; 279(5347):98-102. PubMed ID: 9417034
[TBL] [Abstract][Full Text] [Related]
23. A rational approach to identify inhibitors of Mycobacterium tuberculosis enoyl acyl carrier protein reductase.
Chhabria MT; Parmar KB; Brahmkshatriya PS
Curr Pharm Des; 2013; 19(21):3878-83. PubMed ID: 23477735
[TBL] [Abstract][Full Text] [Related]
24. Mechanism and inhibition of the FabV enoyl-ACP reductase from Burkholderia mallei.
Lu H; Tonge PJ
Biochemistry; 2010 Feb; 49(6):1281-9. PubMed ID: 20055482
[TBL] [Abstract][Full Text] [Related]
25. Cross-docking study on InhA inhibitors: a combination of Autodock Vina and PM6-DH2 simulations to retrieve bio-active conformations.
Stigliani JL; Bernardes-Génisson V; Bernadou J; Pratviel G
Org Biomol Chem; 2012 Aug; 10(31):6341-9. PubMed ID: 22751934
[TBL] [Abstract][Full Text] [Related]
26. Design, synthesis, and biological and crystallographic evaluation of novel inhibitors of Plasmodium falciparum enoyl-ACP-reductase (PfFabI).
Belluti F; Perozzo R; Lauciello L; Colizzi F; Kostrewa D; Bisi A; Gobbi S; Rampa A; Bolognesi ML; Recanatini M; Brun R; Scapozza L; Cavalli A
J Med Chem; 2013 Oct; 56(19):7516-26. PubMed ID: 24063369
[TBL] [Abstract][Full Text] [Related]
27. Designing quinoline-isoniazid hybrids as potent anti-tubercular agents inhibiting mycolic acid biosynthesis.
Alcaraz M; Sharma B; Roquet-Banères F; Conde C; Cochard T; Biet F; Kumar V; Kremer L
Eur J Med Chem; 2022 Sep; 239():114531. PubMed ID: 35759907
[TBL] [Abstract][Full Text] [Related]
28. Analysis of Enoyl-Acyl Carrier Protein Reductase Structure and Interactions Yields an Efficient Virtual Screening Approach and Suggests a Potential Allosteric Site.
Ghattas MA; Mansour RA; Atatreh N; Bryce RA
Chem Biol Drug Des; 2016 Jan; 87(1):131-42. PubMed ID: 26259619
[TBL] [Abstract][Full Text] [Related]
29. Tryptanthrin Analogues as Inhibitors of Enoyl-acyl Carrier Protein Reductase: Activity against Mycobacterium tuberculosis, Toxicity, Modeling of Enzyme Binding.
Duca G; Pogrebnoi S; Boldescu V; Aksakal F; Uncu A; Valica V; Uncu L; Negres S; Nicolescu F; Macaev F
Curr Top Med Chem; 2019; 19(8):609-619. PubMed ID: 30834838
[TBL] [Abstract][Full Text] [Related]
30. Recent Advances and Structural Features of Enoyl-ACP Reductase Inhibitors of Mycobacterium tuberculosis.
Inturi B; Pujar GV; Purohit MN
Arch Pharm (Weinheim); 2016 Nov; 349(11):817-826. PubMed ID: 27775177
[TBL] [Abstract][Full Text] [Related]
31. InhA, a target of the antituberculous drug isoniazid, is involved in a mycobacterial fatty acid elongation system, FAS-II.
Marrakchi H; Lanéelle G; Quémard AK
Microbiology (Reading); 2000 Feb; 146 ( Pt 2)():289-296. PubMed ID: 10708367
[TBL] [Abstract][Full Text] [Related]
32. Enoyl acyl carrier protein reductase inhibitors: an updated patent review (2011 - 2015).
Zitko J; Doležal M
Expert Opin Ther Pat; 2016 Sep; 26(9):1079-94. PubMed ID: 27399249
[TBL] [Abstract][Full Text] [Related]
33. Synthesis and biological activity of diaryl ether inhibitors of malarial enoyl acyl carrier protein reductase. Part 2: 2'-substituted triclosan derivatives.
Freundlich JS; Yu M; Lucumi E; Kuo M; Tsai HC; Valderramos JC; Karagyozov L; Jacobs WR; Schiehser GA; Fidock DA; Jacobus DP; Sacchettini JC
Bioorg Med Chem Lett; 2006 Apr; 16(8):2163-9. PubMed ID: 16466916
[TBL] [Abstract][Full Text] [Related]
34. Structure-based drug design and in vitro testing reveal new inhibitors of enoyl-acyl carrier protein reductases.
Ghattas MA; Eissa NA; Tessaro F; Perozzo R; Scapozza L; Obaid D; Atatreh N
Chem Biol Drug Des; 2019 Aug; 94(2):1545-1555. PubMed ID: 31063658
[TBL] [Abstract][Full Text] [Related]
35. Novel type II fatty acid biosynthesis (FAS II) inhibitors as multistage antimalarial agents.
Schrader FC; Glinca S; Sattler JM; Dahse HM; Afanador GA; Prigge ST; Lanzer M; Mueller AK; Klebe G; Schlitzer M
ChemMedChem; 2013 Mar; 8(3):442-61. PubMed ID: 23341167
[TBL] [Abstract][Full Text] [Related]
36. Molecular modeling studies, synthesis, and biological evaluation of Plasmodium falciparum enoyl-acyl carrier protein reductase (PfENR) inhibitors.
Morde VA; Shaikh MS; Pissurlenkar RR; Coutinho EC
Mol Divers; 2009 Nov; 13(4):501-17. PubMed ID: 19347595
[TBL] [Abstract][Full Text] [Related]
37. The enoyl-[acyl-carrier-protein] reductase (FabI) of Escherichia coli, which catalyzes a key regulatory step in fatty acid biosynthesis, accepts NADH and NADPH as cofactors and is inhibited by palmitoyl-CoA.
Bergler H; Fuchsbichler S; Högenauer G; Turnowsky F
Eur J Biochem; 1996 Dec; 242(3):689-94. PubMed ID: 9022698
[TBL] [Abstract][Full Text] [Related]
38. Diversity in enoyl-acyl carrier protein reductases.
Massengo-Tiassé RP; Cronan JE
Cell Mol Life Sci; 2009 May; 66(9):1507-17. PubMed ID: 19151923
[TBL] [Abstract][Full Text] [Related]
39. Design, development, synthesis, and docking analysis of 2'-substituted triclosan analogs as inhibitors for Plasmodium falciparum enoyl-ACP reductase.
Kapoor N; Banerjee T; Babu P; Maity K; Surolia N; Surolia A
IUBMB Life; 2009 Nov; 61(11):1083-91. PubMed ID: 19859979
[TBL] [Abstract][Full Text] [Related]
40. Crystallographic studies on the binding of isonicotinyl-NAD adduct to wild-type and isoniazid resistant 2-trans-enoyl-ACP (CoA) reductase from Mycobacterium tuberculosis.
Dias MV; Vasconcelos IB; Prado AM; Fadel V; Basso LA; de Azevedo WF; Santos DS
J Struct Biol; 2007 Sep; 159(3):369-80. PubMed ID: 17588773
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
